Print Page | Close Page

 
 

Simulations Plus

Address: 42505 10th St W Suite 103, Lancaster, California. CA 93534
 
Country: USA
 
Sectors: Software Services, Collaborations & Partnerships- R&D
 
Website: http://www.simulations-plus.com
 
- - -
 

About Us

Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide.

 
- - -
 

Sectors

  • Software Services
 
  • Collaborations & Partnerships- R&D
 
- - -
 

Categories

  • Drug Discovery Services
  • Drug Development Services
  • Software
  • Software-3D
  • Software-AI
  • Biosimulation
  • Pharmacokinetic Studies
 
  • Drug Metabolism Studies
  • Drug Design
  • Regulatory Support
  • Pharmacology
  • Toxicology Studies
  • Clinical Research
 
- - -
 

News

 
24th January 2025
 

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

 

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.


The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT™) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

 
- - -
 
Printed: 15-Apr-2026 at 23:23:43 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com